Welcome to our dedicated page for Curis SEC filings (Ticker: CRIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Curis, Inc. (CRIS) SEC filings page brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Form 8-K current reports and related exhibits. These filings provide detailed information on Curis’s financing transactions, licensing and royalty arrangements, asset sales, and Nasdaq listing status, as well as references to its clinical development activities for emavusertib (CA-4948).
Curis’s Form 8-K filings describe material definitive agreements such as securities purchase agreements for registered direct offerings, concurrent private placements, and a PIPE financing involving Series B convertible non-redeemable preferred stock and multiple series of warrants. The filings outline the number and type of securities offered, exercise prices, beneficial ownership limitations, and associated registration rights agreements that govern the resale of shares issuable upon conversion or exercise.
Filings also cover royalty and asset transactions, including the Royalty Interest Purchase Agreement related to Erivedge royalties and the subsequent sale of Curis’s interest in Curis Royalty LLC, which included the Erivedge intellectual property and license agreement. In connection with this sale, Curis reported that it would no longer be entitled to revenues under the Erivedge license and that the liability related to the sale of future royalties would be extinguished, with pro forma financial information provided in an amended Form 8-K.
Investors can review Nasdaq listing and compliance disclosures in Curis’s 8-K reports, where the company discusses notices of non-compliance with the market value of listed securities requirement, its request for a hearing before a Nasdaq panel, and an exception period granted to regain compliance. Additional 8-K items address results of operations and financial condition, prospectus supplements under a shelf registration statement, and corporate slide presentations used in investor meetings.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight key terms, timelines, and potential implications. Users can quickly identify financing structures, changes in royalty streams, and listing risk factors, while still having access to the full underlying documents for deeper review.
Curis, Inc. (Nasdaq: CRIS) has entered into a combined $7.0 million capital raise consisting of a registered direct offering and a concurrent private placement. On 2 July 2025, the company executed a Securities Purchase Agreement with institutional investors to sell (i) 1,538,460 registered shares of common stock and (ii) an equivalent number of pre-funded warrants, each paired with five-year common warrants covering in aggregate 3,076,921 shares. The combined purchase price is $2.275 per share/warrant unit for stock and $2.265 for pre-funded warrant units, implying a modest 0.4% discount for the pre-funded tranche. Gross proceeds are expected to total approximately $7.0 million before $0.5 million in placement fees and up to $0.1 million in reimbursable expenses.
Laidlaw & Company (UK) Ltd. and JonesTrading Institutional Services LLC acted as co-placement agents. Shares are being issued off Curis’ effective Form S-3 shelf (File No. 333-276950); the unregistered warrants and underlying shares rely on the Section 4(a)(2)/Rule 506(b) exemption. Closing is targeted on or before 3 July 2025, subject to customary conditions.
The unregistered warrants are immediately exercisable: pre-funded warrants at $0.01 and common warrants at $2.15, each containing beneficial-ownership caps of 4.99% or 9.99% (adjustable up to 19.99% with notice). In certain hostile fundamental transactions, holders may require cash redemption at fair value calculated via a Black-Scholes model.
A Registration Rights Agreement obliges Curis to file a resale shelf for the warrant shares within 60 days of closing and keep it effective for up to five years, with 1% monthly liquidated damages for filing/effectiveness delays (subject to caps).
Management expects net proceeds, together with existing cash, to fund operations into Q1 2026. Curis simultaneously terminated the April 2024 ATM prospectus under its Cantor/Jones at-the-market facility; the Sales Agreement remains in force but new sales require a refreshed prospectus.
Exhibits include the forms of warrants, Purchase Agreement, Registration Rights Agreement, legal opinion, investor deck, and the related press release.